Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 12/20 | 0.44 |
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.42 |
| ▸ | F11 | P03951 | 2/20 | 0.35 |
| ▸ | P4HB | P07237 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.34 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19358011 | 0.83 | LPL (0.39) | LPLLIPG | |
| SCHEMBL21995500 | 0.81 | CRBN (0.56) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL19434952 | 0.80 | TDO2 (0.41) | LPLLIPGSMN1; SMN2 | |
| SCHEMBL25160569 | 0.79 | LPL (0.39) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL23546470 | 0.79 | CA1 (0.44) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL16880416 | 0.77 | POLB (0.54) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL2755135 | 0.77 | CA1 (0.42) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL16611640 | 0.77 | CA1 (0.42) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL794275 | 0.77 | ALDH1A1 (0.49) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL30712344 | 0.76 | LPL (0.38) | LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4646410-A1 | TUBULIN POLYMERIZATION INHIBITORS | AB Science (FR) | 2025-11-12 | — | — | EP | disclosed |
| US-20250179059-A1 | ANTICANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-06-05 | — | — | US | disclosed |
| US-12162870-B2 | Anticancer compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-12-10 | — | — | US | disclosed |
| WO-2024146923-A1 | TUBULIN POLYMERIZATION INHIBITORS | AB SCIENCE (FR) | 2024-07-11 | — | — | WO | disclosed |
| US-20240199621-A1 | MAP4K4 INHIBITORS | IMPERIAL COLLEGE INNOVATIONS LTD (GB) | 2024-06-20 | — | — | US | disclosed |
| EP-4351560-A1 | ANTICANCER COMPOUNDS | The Regents of the University of California (US) | 2024-04-17 | — | — | EP | disclosed |
| CN-112585147-B | MAP4K4 inhibitors | 帝国理工学院创新有限公司 | 2023-12-05 | — | — | CN | disclosed |
| US-11795169-B2 | MAP4K4 inhibitors | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2023-10-24 | — | — | US | disclosed |
| US-11795169-B2 | MAP4K4 inhibitors | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2023-10-24 | — | — | US | disclosed |
| US-11795169-B2 | MAP4K4 inhibitors | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2023-10-24 | — | — | US | disclosed |
| EP-3694866-A1 | MAP4K4 INHIBITORS | Imperial College Of Science, Technology And Medicine (GB) | 2020-08-19 | — | — | EP | disclosed |
| WO-2019073253-A1 | MAP4K4 INHIBITORS | IMPERIAL INNOVATIONS LIMITED (GB) | 2019-04-18 | — | — | WO | disclosed |
| WO-2019073253-A1 | MAP4K4 INHIBITORS | IMPERIAL INNOVATIONS LIMITED (GB) | 2019-04-18 | — | — | WO | disclosed |
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2016-09-01 | — | — | US | disclosed |
| US-9371320-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-21 | — | — | US | disclosed |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-21 | — | — | US | disclosed |
| EP-2857400-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-04-08 | — | — | EP | disclosed |
| EP-2616443-A1 | PHTALAZINE DERIVATIVES AS JAK1 INHIBITORS | Exelixis, Inc. (US) | 2013-07-24 | — | — | EP | disclosed |
| US-20130165440-A1 | JAK1 Inhibitors | EXELIXIS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| WO-2012037132-A1 | PHTALAZINE DERIVATIVES AS JAK1 INHIBITORS | EXELIXIS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179059-A1 | ANTICANCER COMPOUNDS | BET1, BRD4, BICRA | LPL 4705/4885LIPG 3705/4885CA1 4280/4885 |
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | LPL 3297/4885LIPG 3581/4885CA1 2704/4885 |
| US-20130165440-A1 | JAK1 Inhibitors | JAK1, JAK2, JAK3 | LPL 4337/4885LIPG 4175/4885CA1 4785/4885 |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | LPL 3297/4885LIPG 3581/4885CA1 2704/4885 |
| US-11795169-B2 | MAP4K4 inhibitors | MAP4K4, MAP4K2, MAP4K5 | LPL 4821/4885LIPG 4554/4885CA1 4427/4885 |
| US-20240199621-A1 | MAP4K4 INHIBITORS | MAP4K4, MAP4K2, MAP4K5 | LPL 4821/4885LIPG 4554/4885CA1 4427/4885 |
| US-12162870-B2 | Anticancer compounds | BET1, BRD4, BICRA | LPL 4705/4885LIPG 3705/4885CA1 4280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.